therapeutic / prophylactic agent containing PTH for osteoporosis, wherein the PTH is administered once a week in a unit dose of 200 units

An agent containing parathyroid hormone (PTH) as the active ingredient for use in the treatment or prevention of osteoporosis in a patient, wherein the agent containing PTH to be administered once a week in a unit dose of 200 units to over longer than 48 weeks, and where the patient meets all of the following conditions (1) to (3): (1) age 65 or more; (2) prevalent bone fractures; (3) lower bone density than the average 80% in young asultos and / or degree of atrophy of I or higher.